US Stock MarketDetailed Quotes
MGTX MeiraGTx Holdings
- 5.930
- +0.010+0.17%
Close Nov 22 16:00 ET
- 6.000
- +0.070+1.18%
Post 20:01 ET
463.45MMarket Cap-4941P/E (TTM)
6.045High5.828Low149.73KVolume5.930Open5.920Pre Close890.54KTurnover0.50%Turnover RatioLossP/E (Static)78.15MShares7.60052wk High4.84P/B178.35MFloat Cap3.85052wk Low--Dividend TTM30.08MShs Float30.230Historical High--Div YieldTTM3.67%Amplitude3.490Historical Low5.947Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
MeiraGTx Holdings Stock Forum
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX) announced five poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress in Rome, Italy. The posters highlight the company's advancements in genetic medicine and cell therapy platforms:
1. Optimized AAV manufacturing platform yielding high titers and improved product quality.
2....
MeiraGTx Holdings | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(8.6%),Johnson & Johnson Innovation-JJDC, Inc.(8.6%)
MeiraGTx Holdings PLC: Primary Study Objective of Safety and Tolerability Was Met
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi -4/sh
MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical stage genetic medicine company, has announced the pricing of an underwritten offering of 12,500,000 ordinary shares at $4.00 per share. The offering, expected to close on August 13, 2024, aims to raise $50 million in gross proceeds. Sanofi led the financing with a $30 million equity investment, joined by Perceptive Advisors and other inst...
Dow Jones· just
No comment yet